Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Bevacizumab
100%
Institutional Experience
100%
Unresectable Hepatocellular Carcinoma
100%
Atezolizumab
100%
Line Groups
100%
Subsequent Line
88%
Atezolizumab Plus Bevacizumab
77%
First-line Therapy
33%
Survival Outcomes
33%
Unresectable HCC
33%
Median Overall Survival
22%
Progression-free Survival
22%
Hepatocellular Carcinoma
22%
Methodist
11%
Houston
11%
Liver
11%
Patient Response
11%
Immune Checkpoint Inhibitors
11%
Cancer Center
11%
Immune Response
11%
Clinical Benefit
11%
Patient Selection
11%
Mortality Rate
11%
Clinical Characteristics
11%
Incidence Rate
11%
Predictive Factors
11%
Overall Survival
11%
Liver Function Tests
11%
Kaplan-Meier
11%
Treatment Setting
11%
Treatment Regimen
11%
Single Institution
11%
Liver Malignancy
11%
Bilirubin
11%
Median Progression-free Survival
11%
FDA-approved Drugs
11%
Early Intervention
11%
Albumin Level
11%
Liver Cancer
11%
Treatment Cycle
11%
Number of Treatment
11%
Multi-institutional Study
11%
Safe Application
11%
Observed Trends
11%
Stage 10
11%
Barcelona
11%
Immune Checkpoint
11%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Bevacizumab
100%
Atezolizumab
100%
Overall Survival
30%
Progression Free Survival
30%
Malignant Neoplasm
10%
Mortality Rate
10%
Bilirubin
10%
Liver Cancer
10%
Immune Checkpoint Inhibitor
10%
Albumin
10%
Immunology and Microbiology
Bevacizumab
100%
Atezolizumab
100%
Overall Survival
30%
Progression Free Survival
30%
Immune Response
10%
Mortality Rate
10%
Liver Function
10%
Albumin Level
10%
Immune Checkpoint Inhibitor
10%